Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

The loan is established for a predetermined period (the “term”), at a fixed rate of interest (the “coupon”). Borrowers are on ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

Eli Lilly (NYSE:LLY) shares dropped on Thursday after lowering its full-year outlook amid a decision by CVS Health (NYSE:CVS) to limit access to the company’s popular weight loss drug, Zepbound ...

The trial results add to the growing list of conditions that GLP-1s — the class of drugs that includes Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound — can treat ...

Zepbound has emerged as one of Lilly’s top sellers. Its sales jumped to $2.3 billion in the recently completed first quarter. That’s up from $517 million a year ago, during the drug’s first ...